Full Press Release Details
FDA Grants Orphan Drug Designation To Eidos Therapeutics' Product Candidate, AG10, For Treatment Of Transthyretin Amyloidosis.
BBIO
FDA Grants Orphan Drug Designation To Eidos Therapeutics' Product Candidate, AG10, For Treatment Of Transthyretin Amyloidosis
Key Takeaway: FDA Grants Orphan Drug Designation To Eidos Therapeutics' Product Candidate, AG10, For Treatment Of Transthyretin Amyloidosis